934 related articles for article (PubMed ID: 8855806)
1. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment.
Spagnoli A; Branca F; Spadoni GL; Cianfarani S; Pasquino AM; Argirò G; Vitale S; Robins SP; Boscherini B
J Clin Endocrinol Metab; 1996 Oct; 81(10):3589-93. PubMed ID: 8855806
[TBL] [Abstract][Full Text] [Related]
2. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency.
Högler W; Briody J; Moore B; Lu PW; Cowell CT
Bone; 2005 Nov; 37(5):642-50. PubMed ID: 16139578
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.
Bollerslev J; Møller J; Thomas S; Djøseland O; Christiansen JS
Eur J Endocrinol; 1996 Dec; 135(6):666-71. PubMed ID: 9025710
[TBL] [Abstract][Full Text] [Related]
4. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
Magnusson P; Degerblad M; Sääf M; Larsson L; Thorén M
J Bone Miner Res; 1997 Feb; 12(2):210-20. PubMed ID: 9041052
[TBL] [Abstract][Full Text] [Related]
5. Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH.
Kamp GA; Zwinderman AH; Van Doorn J; Hackeng W; Frölich M; Schönau E; Wit JM
Clin Endocrinol (Oxf); 2002 Sep; 57(3):315-25. PubMed ID: 12201823
[TBL] [Abstract][Full Text] [Related]
6. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
Janssen YJ; Hamdy NA; Frölich M; Roelfsema F
J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
[TBL] [Abstract][Full Text] [Related]
8. Carboxy-terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age.
Lieuw-A-Fa M; Sierra RI; Specker BL
J Bone Miner Res; 1995 Jun; 10(6):849-53. PubMed ID: 7572307
[TBL] [Abstract][Full Text] [Related]
9. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
[TBL] [Abstract][Full Text] [Related]
10. Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?
Colmenares A; González L; Gunczler P; Lanes R
J Pediatr Endocrinol Metab; 2012; 25(7-8):651-7. PubMed ID: 23155689
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of pyridinium crosslinks in short children treated with growth hormone.
Branca F; Spagnoli A; Cianfarani S; Spadoni G; Golden MH; Boscherini B; Valtueña S; Robins SP
J Pediatr Endocrinol Metab; 2002 Jan; 15(1):27-34. PubMed ID: 11826867
[TBL] [Abstract][Full Text] [Related]
12. Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency.
Sartorio A; Arosio M; Conti A; Ferrero S; Porretti S; Faglia G
J Endocrinol Invest; 1999 Mar; 22(3):169-75. PubMed ID: 10219883
[TBL] [Abstract][Full Text] [Related]
13. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.
Kamp GA; Mul D; Waelkens JJ; Jansen M; Delemarre-van de Waal HA; Verhoeven-Wind L; Frölich M; Oostdijk W; Wit JM
J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153
[TBL] [Abstract][Full Text] [Related]
15. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study.
Lanes R; Gunczler P; Esaa S; Weisinger JR
Clin Endocrinol (Oxf); 2002 Dec; 57(6):725-30. PubMed ID: 12460321
[TBL] [Abstract][Full Text] [Related]
16. [Establishment and validation of predictive model of short term responses to recombinant human growth hormone treatment in prepubertal short stature children with various growth hormone secretary statuses].
Su Z; Li YH; Ma HM; Chen HS; DU ML; Gu YF
Zhonghua Er Ke Za Zhi; 2008 Oct; 46(10):757-62. PubMed ID: 19099881
[TBL] [Abstract][Full Text] [Related]
17. Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment.
Soliman A; Rogol AD; Elsiddig S; Khalil A; Alaaraj N; Alyafie F; Ahmed H; Elawwa A
J Pediatr Endocrinol Metab; 2021 Oct; 34(10):1263-1271. PubMed ID: 34291621
[TBL] [Abstract][Full Text] [Related]
18. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children.
Crofton PM; Stirling HF; Schönau E; Kelnar CJ
Clin Endocrinol (Oxf); 1996 Apr; 44(4):385-94. PubMed ID: 8706304
[TBL] [Abstract][Full Text] [Related]
19. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children.
Bakker B; Frane J; Anhalt H; Lippe B; Rosenfeld RG
J Clin Endocrinol Metab; 2008 Feb; 93(2):352-7. PubMed ID: 18000092
[TBL] [Abstract][Full Text] [Related]
20. Short-term changes in bone formation markers following growth hormone (GH) treatment in short prepubertal children with a broad range of GH secretion.
Andersson B; Swolin-Eide D; Magnusson P; Albertsson-Wikland K
Clin Endocrinol (Oxf); 2015 Jan; 82(1):91-9. PubMed ID: 24818653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
